Skip to main content
. 2015 Jun;12(2):117–125. doi: 10.7497/j.issn.2095-3941.2015.0012

Figure 2.

Figure 2

Kaplan-Meier curves for OS of 62 patients with stages I-IV CSCLC. The median OS of 3-drug group was not significantly longer than that of 2-drug group (24.0 vs. 17.5 months, P=0.457). OS, overall survival; CSCLC, combined small-cell lung cancer.